


Editors

Ali Nokhodchi

Gary P. Martin

# Pulmonary Drug Delivery

## Advances and Challenges



# **Pulmonary Drug Delivery**

Advances and Challenges

Edited by

ALI NOKHODCHI AND GARY P. MARTIN



**WILEY**

This edition first published 2015  
©2015 John Wiley & Sons, Ltd

*Registered office*

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services, and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com](http://www.wiley.com).

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs, and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks, or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. It is sold on the understanding that the publisher is not engaged in rendering professional services and neither the publisher nor the author shall be liable for damages arising herefrom. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data applied for.*

A catalogue record for this book is available from the British Library.

ISBN: 9781118799543

Set in 9/11pt TimesLTStd by SPi Global, Chennai, India  
Printed and bound in Singapore by Markono Print Media Pte Ltd

# Pulmonary Drug Delivery

# **Advances in Pharmaceutical Technology**

A Wiley Book Series

Series Editors:

**Dennis Douroumis, University of Greenwich, UK**  
**Alfred Fahr, Friedrich-Schiller University of Jena, Germany**  
**Jürgen Siepmann, University of Lille, France**  
**Martin Snowden, University of Greenwich, UK**  
**Vladimir Torchilin, Northeastern University, USA**

---

## **Titles in the Series**

Hot-Melt Extrusion: Pharmaceutical Applications  
Edited by Dionysios Douroumis

Drug Delivery Strategies for Poorly Water-Soluble Drugs  
Edited by Dionysios Douroumis and Alfred Fahr

Computational Pharmaceutics Application of Molecular Modeling in Drug Delivery  
Edited by Defang Ouyang and Sean C. Smith

## **Forthcoming titles:**

Novel Delivery Systems for Transdermal and Intradermal Drug Delivery  
Edited by Ryan F. Donnelly and Thakur Raghu Raj Singh

# List of Contributors

**Iman M. Alfagih**, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, UK; College of Pharmacy, Woman Students Medical Studies and Science Sections, King Saud University, Saudi Arabia

**Hatim S. AlKhatib**, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Jordan, Jordan

**Karim Amighi**, Laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), Belgium

**Anna Giulia Balducci**, Interdepartmental Center, Biopharmanet-TEC, University of Parma, Italy; PlumeStars s.r.l., Parma, Italy

**Jaleh Barar**, Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran

**David Barling**, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, University of Monash, Australia

**Ruggero Bettini**, Department of Pharmacy, University of Parma, Italy

**Francesca Buttini**, Department of Pharmacy, University of Parma, Italy; Institute of Pharmaceutical Science, King's College London, UK

**Simone R. Carvalho**, Division of Pharmaceutics, The University of Texas at Austin, College of Pharmacy, USA

**Lai Wah Chan**, GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, Singapore

**Paolo Colombo**, Department of Pharmacy, University of Parma, Italy

**Nabil Darwazeh**, Tabuk Pharmaceutical Research Co., Amman, Jordan

**Stephen Dubsky**, Department of Mechanical and Aerospace Engineering, Faculty of Engineering, Monash University, Australia

**Marie-Pierre Flament**, Faculty of Engineering and Management of Health, University of Lille 2, France

**Ben Forbes**, Institute of Pharmaceutical Science, King's College London, UK

**Andreas Fouras**, Department of Mechanical and Aerospace Engineering, Faculty of Engineering, Monash University, Australia

**Lucila Garcia-Contreras**, Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, USA

**Mark Gumbleton**, Welsh School of Pharmacy, Cardiff University, Wales

**Hamed Hamishehkar**, Drug Applied Research Center, Tabriz University of Medical Sciences, Iran

**Karen Hapgood**, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, University of Monash, Australia

**Paul Wan Sia Heng**, GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, Singapore

**Gillian A. Hutcheon**, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, UK

**Mariam Ibrahim**, Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, USA

**Rim Jawad**, Institute of Pharmaceutical Science, King's College London, UK

**Waseem Kaialy**, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, UK

**Nitesh K. Kunda**, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, UK

**Orest Lastow**, Iconovo AB, Medicon Village, Lund, Sweden

**Celine Valeria Liew**, GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, Singapore

**Gary P. Martin**, Institute of Pharmaceutical Science, King's College London, UK

**David Morton**, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, University of Monash, Australia

**Sami Nazzal**, College of Health and Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, USA

**Ali Nokhodchi**, School of Life Sciences, University of Sussex, UK; Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran

**Yadollah Omid**, Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran

**Jay I. Peters**, Department of Medicine, Division of Pulmonary Diseases/Critical Care Medicine, The University of Texas Health Science Center at San Antonio, USA

**Yahya Rahimpour**, Biotechnology Research Center and Student Research Committee, Tabriz University of Medical Sciences, Iran

**Paul G. Royall**, Institute of Pharmaceutical Science, King's College London, UK

**Nathalie Hauet Richer**, Institute of Pharmaceutical Science, King's College London, UK

**Imran Y. Saleem**, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, UK

**Al Sayyed Sallam**, Al Taqaddom Pharmaceutical Industries Co., Jordan

**Bernice Mei Jin Tan**, GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, Singapore

**Rahul K. Verma**, Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, USA

**Alan B. Watts**, College of Pharmacy, Drug Dynamics Institute, The University of Texas at Austin, USA

**Nathalie Wauthoz**, Laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), Belgium

**Robert O. Williams III**, Division of Pharmaceutics, The University of Texas at Austin, College of Pharmacy, USA





# Advances in Pharmaceutical Technology

## Series Preface

The series *Advances in Pharmaceutical Technology* covers the principles, methods, and technologies that the pharmaceutical industry use to turn a candidate molecule or new chemical entity into a final drug form and hence a new medicine. The series will explore means of optimizing the therapeutic performance of a drug molecule by designing and manufacturing the best and most innovative of new formulations. The processes associated with the testing of new drugs, the key steps involved in the clinical trials process, and the most recent approaches utilized in the manufacture of new medicinal products will all be reported. The focus of the series will very much be on new and emerging technologies and the latest methods used in the drug development process.

The topics covered by the series include:

**Formulation:** The manufacture of tablets in all forms (caplets, dispersible, and fast-melting) will be described, as will capsules, suppositories, solutions, suspensions and emulsions, aerosols and sprays, injections, powders, ointments and creams, sustained release, and the latest transdermal products. The developments in engineering associated with fluid, powder and solids handling, solubility enhancement, colloidal systems including the stability of emulsions and suspensions will also be reported within the series. The influence of formulation design on the bioavailability of a drug will be discussed and the importance of formulation with respect to the development of an optimal final new medicinal product will be clearly illustrated.

**Drug Delivery:** The use of various excipients and their role in drug delivery will be reviewed. Amongst the topics to be reported and discussed will be a critical appraisal of the current range of modified-release dosage forms currently in use and also those under development. The design and mechanism(s) of controlled release systems including; macromolecular drug delivery, microparticulate controlled drug delivery, the delivery of biopharmaceuticals, delivery vehicles created for gastro-intestinal tract targeted delivery, transdermal delivery, and systems designed specifically for drug delivery to the lung will all be reviewed and critically appraised. Further site-specific systems used for the delivery of drugs across the blood brain barrier including dendrimers, hydrogels, and new innovative biomaterials will be reported.

**Manufacturing:** The key elements of the manufacturing steps involved in the production of new medicines will be explored in this series. The importance of crystallization; batch and continuous processing, seeding; mixing including a description of the key engineering principles relevant to the manufacture of new medicines will all be reviewed and reported. The fundamental processes of quality control including good laboratory practice (GLP), good manufacturing practice (GMP), quality by design (QbD), the Deming cycle; regulatory requirements and the design of appropriate robust statistical sampling procedures for the control of raw materials will all be an integral part of this book series.

An evaluation of the current analytical methods used to determine drug stability, the quantitative identification of impurities, contaminants, and adulterants in pharmaceutical materials will be

described as will the production of therapeutic bio-macromolecules, bacteria, viruses, yeasts, molds, prions, and toxins through chemical synthesis and emerging synthetic/molecular biology techniques. The importance of packaging including the compatibility of materials in contact with drug products and their barrier properties will also be explored.

*Advances in Pharmaceutical Technology* is intended as a comprehensive one-stop shop for those interested in the development and manufacture of new medicines. The series will appeal to those working in the pharmaceutical and related industries, both large and small, and will also be valuable to those who are studying and learning about the drug development process and the translation of those drugs into new life saving and life-enriching medicines.

*Dennis Douroumis*

*Alfred Fahr*

*Juergen Siepmann*

*Martin Snowden*

*Vladimir Torchilin*

# Preface

One of the first axioms imparted to students interested in formulating drugs for human and animal administration is that a drug (or active pharmaceutical ingredient) itself does not comprise a medicine. The drug has first to be formulated into a medicine that can be ingested by the patient. The most popular medicinal form (both with patient and healthcare workers), easiest to take or administer, dose-reproducible, cheapest, most stable, and safest form is generally acknowledged to be the tablet. To achieve these desirable characteristics, a large number of excipients (or 'non-pharmacologically active' materials) have to be included. These could include, for example, fillers, lubricants, glidants, disintegrants, colours, coating agents, etc.

However the challenges of treating diseases, such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, infections, tuberculosis, and lung cancer which involves the airways, render the tablet a less advantageous choice compared with the patient employing an inhaled formulation as a means of therapeutic management. This is because an inhaled drug can be delivered locally at a lower dose and hence with fewer side-effects compared to that taken via the gastrointestinal tract. In addition, it might appear initially that some of the formulation issues might be reduced because most inhaled formulations comprise either none or possibly only one or two excipients (in addition to the drug). However this tenet is clearly false. For example currently, over 40% of patients suffering from asthma and chronic obstructive pulmonary disease use dry powder inhaler (DPI) formulations and this number is expected to grow in the future; and despite extensive research on DPIs during the last 40 years, some of these formulations may only deliver 10–20% of the inspired drug to the lungs. A core requirement for the effective clinical management of such respiratory diseases often, therefore, depends on the efficient delivery of aerosolised drugs to the airways. For efficiency to be optimised prior to the innovation of a new medicinal aerosol, a closely integrated triumvirate of fundamental factors, namely the patient, the formulation and the device, have to be considered both individually and holistically in the development process. One of the first steps of a development process should be to define the product specifications which combine these three essential factors into a user-requirement specification. Such a specification must encompass an appreciation of the patient requirements, involving an understanding of the structure of the airways and the challenges of separate patient groups such as children and the elderly, and acknowledge the impact of disease (e.g. lung cancer) upon the delivery of the drug. To this end, the functional imaging of the airways might assist in improving pulmonary delivery. As regards the formulation of drugs for inhaled dosage forms, then the challenges are many and encompass the following: the methods by which the efficiency of delivery (and dissolution) of such medicines can be assessed *in vitro*; the strategies for formulating poorly soluble active agents; the development of novel macromolecular, micro- and nanoparticulate systems; and the techniques which are developed to assess satisfactory powder blending. The importance of understanding the physicochemistry (including surface roughness) of the so-called inactive excipients, such as lactose, in dry powder formulations and the manner in which these can be manipulated (by particle engineering) is often under-appreciated. However improvements in formulating the drug in powder or suspended form cannot be carried out without appreciating the capabilities of

the device in which it is to be both packaged and presented. The development of the aerosol medicine can then proceed according to quality by design approaches.

As editors, we have been privileged to gain the cooperation of leading expert scientists to contribute to this book, providing both an overview of their research knowledge and presenting first-hand experiences of medicine design. We believe that this proffers an accessible overview to this fast-moving and complex field, and provides the readers with a sound basis for understanding some of the key issues involved. We hope that it will inspire future scientific and technological endeavour to improve the formulation of inhaled dosage forms such that ultimately they will possess all the desirable characteristics of the tablet form (discussed earlier).

The book is written primarily for postgraduate (PhD/Masters) level for readers who require a fast-route basic understanding of the current key issues of pulmonary drug delivery formulation, including device design, powder and particle engineering, and patient considerations. This book is useful for pharmacy students at their final year, pharmaceutical sciences degree courses, postgraduate students working in the inhalation field and scientists working in the industrial sector.

*Ali Nokhodchi*  
*Gary P. Martin*  
*April, 2015*

# Contents

<i>List of Contributors</i>	xiii
<i>Series Preface</i>	xvii
<i>Preface</i>	xix

<b>1. Lung Anatomy and Physiology and Their Implications for Pulmonary Drug Delivery</b>	<b>1</b>
<i>Rahul K. Verma, Mariam Ibrahim, and Lucila Garcia-Contreras</i>	
1.1 Introduction	2
1.2 Anatomy and Physiology of Lungs	2
1.2.1 Macro- and Microstructure of the Airways and Alveoli as It Pertains to Drug Delivery	2
1.2.2 Lung Surfactant	4
1.2.3 Pulmonary Blood Circulation	5
1.3 Mechanisms of Aerosol Deposition	5
1.3.1 Impaction	6
1.3.2 Sedimentation	6
1.3.3 Interception	6
1.3.4 Diffusion	7
1.4 Drug Absorption	7
1.4.1 Mechanisms of Drug Absorption from the Lungs	7
1.5 Physiological Factors Affecting the Therapeutic Effectiveness of Drugs Delivered by the Pulmonary Route	8
1.5.1 Airway Geometry	8
1.5.2 Inhalation Mode	8
1.5.3 Airflow Rate	9
1.5.4 Mechanism of Particle Clearance	9
1.5.5 Lung Receptors	10
1.5.6 Disease States	11
1.5.7 Effect of Age and Gender Difference	11
1.6 Computer Simulations to Describe Aerosol Deposition in Health and Disease	11
1.6.1 Semiempirical Models	12
1.6.2 Deterministic Models	12
1.6.3 Trumpet Models (One-Dimensional)	12
1.6.4 Stochastic, Asymmetric Generation Models	13
1.6.5 Computation Fluid Dynamics (CFD)-Based Model	13

1.7	Conclusions	13
	References	14
<b>2.</b>	<b>The Role of Functional Lung Imaging in the Improvement of Pulmonary Drug Delivery</b>	<b>19</b>
	<i>Andreas Fouras and Stephen Dubsky</i>	
2.1	Introduction	19
2.1.1	Particle Deposition	20
2.1.2	Regional Action of Delivered Drug	22
2.1.3	The Role of Functional Lung Imaging in Pulmonary Drug Delivery	22
2.2	Established Functional Lung Imaging Technologies	23
2.2.1	Computed Tomography	23
2.2.2	Ventilation Measurement using 4DCT Registration-based Methods	24
2.2.3	Hyperpolarized Magnetic Resonance Imaging	24
2.2.4	Electrical Impedance Tomography	25
2.2.5	Nuclear Medical Imaging (PET/SPECT)	25
2.3	Emerging Technologies	26
2.3.1	Phase-contrast Imaging	26
2.3.2	Grating Interferometry	27
2.3.3	Propagation-based Phase-contrast Imaging	28
2.3.4	Functional Lung Imaging using Phase Contrast	28
2.3.5	Laboratory Propagation-based Phase-contrast Imaging	29
2.4	Conclusion	30
	References	31
<b>3.</b>	<b>Dry Powder Inhalation for Pulmonary Delivery: Recent Advances and Continuing Challenges</b>	<b>35</b>
	<i>Simone R. Carvalho, Alan B. Watts, Jay I. Peters, and Robert O. Williams III</i>	
3.1	Introduction	36
3.2	Dry Powder Inhaler Devices	37
3.2.1	Overview	37
3.2.2	Recent Innovations in Dry Powder Inhaler Technology	39
3.3	New Developments in DPI Formulations and Delivery	43
3.3.1	Particle Surface Modification	43
3.3.2	Particle Engineering Technology for Pulmonary Delivery	44
3.4	Characterization Methods of Dry Powder Inhaler Formulations	50
3.5	Conclusion	52
	References	53
<b>4.</b>	<b>Pulmonary Drug Delivery to the Pediatric Population – A State-of-the-Art Review</b>	<b>63</b>
	<i>Marie-Pierre Flament</i>	
4.1	Introduction	63
4.2	Patient Consideration	64
4.2.1	Anatomy and Physiology of Children's Lungs	64

4.2.2	Nasal Versus Oral Inhalation	65
4.2.3	Patient-related Factors Influencing Aerosol Deposition	66
4.2.4	Age and Dosage Forms of Choice	67
4.3	Delivery Systems for the Pediatric Population	69
4.3.1	Nebulizers	69
4.3.2	Pressurized Metered Dose Inhalers	72
4.3.3	Dry Powder Inhalers	73
4.3.4	Interfaces	74
4.4	Recommendations	80
4.5	Conclusion	82
	References	82
<b>5.</b>	<b>Formulation Strategies for Pulmonary Delivery of Poorly Soluble Drugs</b>	<b>87</b>
	<i>Nathalie Wauthoz and Karim Amighi</i>	
5.1	Introduction	88
5.1.1	<i>In vivo</i> Fate of Inhaled Poorly Water-soluble Drugs	89
5.1.2	The Pharmacokinetics of Inhaled Poorly Water-soluble Drugs Administered for Local and Systemic Action	92
5.1.3	Formulation Strategies for Pulmonary Delivery of Poorly Water-soluble Drugs	93
5.2	Co-solvents	93
5.3	Cyclodextrins	97
5.4	PEGylation	99
5.5	Reduction of Size to Micro-/Nanoparticles	100
5.5.1	Nanocrystal Suspension	101
5.5.2	Nanocrystals in a Hydrophilic Matrix System	102
5.5.3	Nanoclusters	103
5.6	Solid Dispersion/Amorphization	103
5.7	Micelles	106
5.8	Liposomes	108
5.9	Solid Lipid Nanoparticles and Nanostructured Lipid Carriers	110
5.10	Conclusion	111
	References	114
<b>6.</b>	<b>Lipidic Micro- and Nano-Carriers for Pulmonary Drug Delivery – A State-of-the-Art Review</b>	<b>123</b>
	<i>Yahya Rahimpour, Hamed Hamishehkar, and Ali Nokhodchi</i>	
6.1	Introduction	124
6.2	Pulmonary Drug Delivery	125
6.3	Liposomal Pulmonary Delivery	126
6.4	Nebulization of Liposomes	126
6.5	Liposomal Dry-powder Inhalers	128
6.6	Solid Lipid Microparticles in Pulmonary Drug Delivery	129
6.7	Solid Lipid Nanoparticles in Pulmonary Drug Delivery	131
6.8	Nanostructured Lipid Carrier (NLC) in Pulmonary Drug Delivery	133



6.9	Nanoemulsions in Pulmonary Drug Delivery	134
6.10	Conclusion and Perspectives	135
	References	136
<b>7.</b>	<b>Chemical and Compositional Characterisation of Lactose as a Carrier in Dry Powder Inhalers</b>	<b>143</b>
	<i>Rim Jawad, Gary P. Martin and Paul G. Royall</i>	
7.1	Introduction	144
7.2	Production of Lactose	145
7.3	Lactose: Chemical Forms, Solid-State Composition, Physicochemical Properties	147
7.4	Epimerisation of Lactose	150
7.5	Analysis of Lactose	151
7.5.1	Powder X-ray Diffraction	152
7.5.2	Nuclear Magnetic Resonance	153
7.5.3	Infrared Spectroscopy	156
7.5.4	Differential Scanning Calorimetry	157
7.5.5	Polarimetry	158
7.6	The Influence of the Chemical and Solid-State Composition of Lactose Carriers on the Aerosolisation of DPI Formulations	159
7.7	Conclusions	163
	References	163
<b>8.</b>	<b>Particle Engineering for Improved Pulmonary Drug Delivery Through Dry Powder Inhalers</b>	<b>171</b>
	<i>Waseem Kaialy and Ali Nokhodchi</i>	
8.1	Introduction	172
8.2	Dry Powder Inhalers	172
8.3	Particle Engineering to Improve the Performance of DPIs	172
8.3.1	Crystallization	173
8.3.2	Spray-drying	174
8.3.3	Spray-freeze-drying	177
8.3.4	Supercritical Fluid Technology	177
8.3.5	Pressure Swing Granulation (PSG) Technique	178
8.4	Engineered Carrier Particles for Improved Pulmonary Drug Delivery from Dry Powder Inhalers	178
8.5	Relationships between Physical Properties of Engineered Particles and Dry Powder Inhaler Performance	182
8.5.1	Particle Size	182
8.5.2	Flow Properties	184
8.5.3	Particle Shape	185
8.5.4	Particle Surface Texture	187
8.5.5	Fine Particle Additives	188
8.5.6	Surface Area	188
8.6	Conclusions	189
	References	189